セッション
＜司会の言葉＞
To realize Precision Medicine for adjuvant chemotherapy for resected colon cancer, there is a precondition that the risk of recurrence for individual patients and the onset/degree of adverse events associated with postoperative adjuvant chemotherapy （risk/benefit assessment） must be accurately predicted. In recent years, the usefulness of the "Oncotype DX test" genomic test to predict the risk of recurrence following colon cancer resection has been reported in our country. The results of a large-scale joint international phase III study （IDEA project, three months vs. six months, N>10,500 cases） to verify an optimal administration period will be reported soon. Furthermore, based on the improvement of treatment results associated with the introduction of Complete Mesocolic Excision （CME） and a change in attitude towards lymph node dissection in Europe and the United States, the standard treatment of uniformly administering oxaliplatin to Stage III colon cancer patients （including high-risk Stage II patients） has been questioned. In this symposium, we have invited Top Opinion Leaders （TOLs） from around the world with the aim of forming a consensus among Japan, the United States and Europe, and taking the first step in Precision Medicine. We hope that this symposium will allow for genuine discussions with all in attendance in this venue on what kinds of clinical questions will need to be resolved to further realize Precision Medicine in the future.
To realize Precision Medicine for adjuvant chemotherapy for resected colon cancer, there is a precondition that the risk of recurrence for individual patients and the onset/degree of adverse events associated with postoperative adjuvant chemotherapy （risk/benefit assessment） must be accurately predicted. In recent years, the usefulness of the "Oncotype DX test" genomic test to predict the risk of recurrence following colon cancer resection has been reported in our country. The results of a large-scale joint international phase III study （IDEA project, three months vs. six months, N>10,500 cases） to verify an optimal administration period will be reported soon. Furthermore, based on the improvement of treatment results associated with the introduction of Complete Mesocolic Excision （CME） and a change in attitude towards lymph node dissection in Europe and the United States, the standard treatment of uniformly administering oxaliplatin to Stage III colon cancer patients （including high-risk Stage II patients） has been questioned. In this symposium, we have invited Top Opinion Leaders （TOLs） from around the world with the aim of forming a consensus among Japan, the United States and Europe, and taking the first step in Precision Medicine. We hope that this symposium will allow for genuine discussions with all in attendance in this venue on what kinds of clinical questions will need to be resolved to further realize Precision Medicine in the future.
Spoken in English
